Should the patent system for new medicines be abolished?

dc.contributor.author	DiMasi, JA
dc.contributor.author	Grabowski, HG
dc.coverage.spatial	United States
dc.date.accessioned	2013-04-23T16:54:45Z
dc.date.issued	2007-11
dc.identifier	https://www.ncbi.nlm.nih.gov/pubmed/17952100
dc.identifier	6100393
dc.identifier.eissn	1532-6535
dc.identifier.uri	https://hdl.handle.net/10161/6721
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Clin Pharmacol Ther
dc.relation.isversionof	10.1038/sj.clpt.6100393
dc.subject	Biomedical Research
dc.subject	Commerce
dc.subject	Cost-Benefit Analysis
dc.subject	Drug Costs
dc.subject	Drug Industry
dc.subject	Financing, Government
dc.subject	Humans
dc.subject	Insurance Coverage
dc.subject	Legislation, Drug
dc.subject	Orphan Drug Production
dc.subject	Patents as Topic
dc.subject	Pharmaceutical Preparations
dc.subject	Public Policy
dc.subject	United States
dc.title	Should the patent system for new medicines be abolished?
dc.type	Journal article
pubs.author-url	https://www.ncbi.nlm.nih.gov/pubmed/17952100
pubs.begin-page	488
pubs.end-page	490
pubs.issue	5
pubs.organisational-group	Duke
pubs.organisational-group	Economics
pubs.organisational-group	Trinity College of Arts & Sciences
pubs.publication-status	Published
pubs.volume	82

Files

Now showing 1 - 1 of 1